These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 20082866)
1. Effect of dipeptidyl peptidase-IV (DPP-IV) inhibitor (Vildagliptin) on peripheral nerves in streptozotocin-induced diabetic rats. Jin HY; Liu WJ; Park JH; Baek HS; Park TS Arch Med Res; 2009 Oct; 40(7):536-44. PubMed ID: 20082866 [TBL] [Abstract][Full Text] [Related]
2. A novel long acting DPP-IV inhibitor PKF-275-055 stimulates β-cell proliferation resulting in improved glucose homeostasis in diabetic rats. Akarte AS; Srinivasan BP; Gandhi S Biochem Pharmacol; 2012 Jan; 83(2):241-52. PubMed ID: 22015634 [TBL] [Abstract][Full Text] [Related]
3. Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes. Kodera R; Shikata K; Takatsuka T; Oda K; Miyamoto S; Kajitani N; Hirota D; Ono T; Usui HK; Makino H Biochem Biophys Res Commun; 2014 Jan; 443(3):828-33. PubMed ID: 24342619 [TBL] [Abstract][Full Text] [Related]
4. Vildagliptin selectively ameliorates GLP-1, GLUT4, SREBP-1c mRNA levels and stimulates β-cell proliferation resulting in improved glucose homeostasis in rats with streptozotocin-induced diabetes. Akarte AS; Srinivasan BP; Gandhi S J Diabetes Complications; 2012; 26(4):266-74. PubMed ID: 22626875 [TBL] [Abstract][Full Text] [Related]
5. Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats. Liu WJ; Xie SH; Liu YN; Kim W; Jin HY; Park SK; Shao YM; Park TS J Pharmacol Exp Ther; 2012 Feb; 340(2):248-55. PubMed ID: 22025647 [TBL] [Abstract][Full Text] [Related]
6. Beneficial effects of PKF275-055, a novel, selective, orally bioavailable, long-acting dipeptidyl peptidase IV inhibitor in streptozotocin-induced diabetic peripheral neuropathy. Bianchi R; Cervellini I; Porretta-Serapiglia C; Oggioni N; Burkey B; Ghezzi P; Cavaletti G; Lauria G J Pharmacol Exp Ther; 2012 Jan; 340(1):64-72. PubMed ID: 21984837 [TBL] [Abstract][Full Text] [Related]
7. Chronic DPP-IV inhibition with PKF-275-055 attenuates inflammation and improves gene expressions responsible for insulin secretion in streptozotocin induced diabetic rats. Akarte AS; Srinivasan BP; Gandhi S; Sole S Eur J Pharm Sci; 2012 Sep; 47(2):456-63. PubMed ID: 22800967 [TBL] [Abstract][Full Text] [Related]
8. Vildagliptin ameliorates oxidative stress and pancreatic beta cell destruction in type 1 diabetic rats. Ávila Dde L; Araújo GR; Silva M; Miranda PH; Diniz MF; Pedrosa ML; Silva ME; de Lima WG; Costa DC Arch Med Res; 2013 Apr; 44(3):194-202. PubMed ID: 23523961 [TBL] [Abstract][Full Text] [Related]
9. Vildagliptin increases butyrate-producing bacteria in the gut of diabetic rats. Zhang Q; Xiao X; Li M; Yu M; Ping F; Zheng J; Wang T; Wang X PLoS One; 2017; 12(10):e0184735. PubMed ID: 29036231 [TBL] [Abstract][Full Text] [Related]
10. Relationships between the islets blood flow, nitric oxide, insulin, and cytosolic calcium in rat pancreatic islets: effects of DPP-IV inhibitor vildagliptin. Akarte AS; Srinivasan BP; Gandhi S Eur J Pharm Sci; 2012 Apr; 45(5):546-51. PubMed ID: 22155545 [TBL] [Abstract][Full Text] [Related]
11. Favorable effects of vildagliptin on metabolic and cognitive dysfunctions in streptozotocin-induced diabetic rats. El Batsh MM; El Batch MM; Shafik NM; Younos IH Eur J Pharmacol; 2015 Dec; 769():297-305. PubMed ID: 26607467 [TBL] [Abstract][Full Text] [Related]
12. No Additional Effect of DPP-4 Inhibitor on Preventing Atrial Fibrosis in Streptozotocin-Induced Diabetic Rat as Compared With Sulfonylurea. Hayami N; Sekiguchi A; Iwasaki YK; Murakawa Y; Yamashita T Int Heart J; 2016 May; 57(3):336-40. PubMed ID: 27149999 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of dipeptidyl peptidase-4 by vildagliptin during glucagon-like Peptide 1 infusion increases liver glucose uptake in the conscious dog. Edgerton DS; Johnson KM; Neal DW; Scott M; Hobbs CH; Zhang X; Duttaroy A; Cherrington AD Diabetes; 2009 Jan; 58(1):243-9. PubMed ID: 18840785 [TBL] [Abstract][Full Text] [Related]
14. Mechanism-based population modelling of the effects of vildagliptin on GLP-1, glucose and insulin in patients with type 2 diabetes. Landersdorfer CB; He YL; Jusko WJ Br J Clin Pharmacol; 2012 Mar; 73(3):373-90. PubMed ID: 22442825 [TBL] [Abstract][Full Text] [Related]
15. Antihyperglycemic effects of ASP8497 in streptozotocin-nicotinamide induced diabetic rats: comparison with other dipeptidyl peptidase-IV inhibitors. Tahara A; Matsuyama-Yokono A; Nakano R; Someya Y; Hayakawa M; Shibasaki M Pharmacol Rep; 2009; 61(5):899-908. PubMed ID: 19904014 [TBL] [Abstract][Full Text] [Related]